Key result
Inhibiting troponin I-interacting kinase reduces oxidative stress and cell death in ischemia-reperfusion animal models.
Why the study?
Does genetic loss or pharmacological inhibition of troponin I-interacting kinase reduce oxidative stress, injury, and adverse remodeling in an animal model of ischemia-reperfusion?
Does genetic loss or pharmacological inhibition of troponin I-interacting kinase reduce oxidative stress, injury, and adverse remodeling in an animal model of ischemia-reperfusion?
Inhibition of troponin I-interacting kinase may protect against ischemia-reperfusion injury by limiting oxidative stress and adverse remodeling in preclinical models.
Should not change clinical practice; hypothesis-generating for troponin I-interacting kinase inhibition in ischemia-reperfusion.
I schemia-reperfusion injury is strongly associated with increased oxidative stress, mitochondrial dysfunction, and cell death.These processes are diminished in an animal model of ischemia-reperfusion by the genetic loss or pharmacological inhibition of troponin I-interacting kinase.Inhibition of the Cardiomyocyte-Specific Troponin I-Interacting Kinase Limits Oxidative Stress, Injury, and Adverse Remodeling due to Ischemic Heart Disease
No takes yet. Share an insight, caveat, or question.
Abraham et al. (2014) studied Ischemic Heart Disease. Genetic loss or pharmacological inhibition of troponin I-interacting kinase was evaluated on Oxidative stress, mitochondrial dysfunction, and cell death. Genetic loss or pharmacological inhibition of troponin I-interacting kinase diminished oxidative stress, mitochondrial dysfunction, and cell death in an animal model of ischemia-reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: